-
Daiichi Sankyo2025-04-08 08:00:44DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast
-
Daiichi Sankyo2025-04-04 08:38:33ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2
-
Daiichi Sankyo2025-04-04 08:37:19ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in
-
Daiichi Sankyo2025-03-06 15:57:51ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic
-
Daiichi Sankyo2025-01-31 15:16:20Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated
-
Daiichi Sankyo2025-01-22 06:59:30Survey reveals: 88% of Western Europeans would like better information on breast cancer, misconceptions and
-
Daiichi Sankyo2024-12-24 08:26:44Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
-
Daiichi Sankyo2024-11-25 15:22:25Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With
-
Daiichi Sankyo2024-07-15 09:32:07Daiichi Sankyo Opens New Affiliate for Oncology in Greece
-
Daiichi Sankyo2024-08-06 16:38:16New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse